Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 20:58 | 2026-04-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $105.47 | 1,750 | $184,573 | 59,003 | -2.9% |
| 2026-03-27 23:33 | 2026-03-26 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $104.24 | 24,765 | $2,581,504 | 60,753 | -29.0% |
| 2026-01-28 05:20 | 2026-01-27 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $83.13 | 46,203 | $3,841,036 | 60,320 | -43.4% |
| 2026-01-22 01:15 | 2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $82.48 | 8,588 | $708,338 | 78,077 | -9.9% |
| 2025-04-23 23:30 | 2025-04-22 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $46.00 | 1,756 | $80,776 | 61,065 | -2.8% |
| 2025-03-15 01:20 | 2025-03-12 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $58.73 | 24,903 | $1,462,553 | 62,821 | -28.4% |
| 2025-01-18 01:45 | 2025-01-16 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $0.00 | 3,918 | $0 | 62,821 | -5.9% |
| 2024-09-13 23:35 | 2024-09-11 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $44.49 | 14,203 | $631,872 | 34,960 | -28.9% |
| 2024-04-20 03:05 | 2024-04-18 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $25.11 | 1,234 | $30,986 | 37,163 | -3.2% |
| 2024-03-02 04:45 | 2024-02-29 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer; Chief Financial Officer | Pharmaceutical Preparations | OPT+S | $31.60 | 24,187 | $764,365 | 38,397 | -38.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.